Surfactant protein B (SP-B) is an essential constituent of pulmonary surfactant. SP-B is
synthesized in alveolar type II cells as a preproprotein and processed to the mature peptide …

Protein supplementation therapy using in vitro-transcribed (IVT) mRNA for genetic diseases
contains huge potential as a new class of therapy. From the early ages of synthetic mRNA …

Surfactant therapy is an established part of routine clinical management of babies with
respiratory distress syndrome. An initial dose of about 100 mg/kg is usually needed to …

▪ Abstract A number of conditions, such as pneumonia, trauma, or systemic sepsis arising
from the gut, may result in the acute respiratory distress syndrome (ARDS). Because of its …

Objective: To evaluate lung transplantation for treatment of surfactant protein B (SP-B)
deficiency. Study design: We compared surfactant composition and function from …

Objective. To compare the relative safety and efficacy of Infasurf (calf lung surfactant extract;
ONY, Inc, Amherst, NY, IND# 27169) versus Survanta (Beractant, Ross Laboratories …

Inherited disorders of pulmonary surfactant-associated proteins are rare but provide
important insights into unique mechanisms of surfactant dysfunction. Recessive loss-of …

The alveolar type II epithelial (ATII) cell is highly specialised for the synthesis and storage, in
intracellular lamellar bodies, of phospholipid destined for secretion as pulmonary surfactant …

Abstract Surfactant protein B (SP-B)−/− mice die of lethal respiratory distress syndrome
shortly after birth. Alveolar type II epithelial cells in SP-B–deficient mice are characterized by …

Whereas decreased concentrations of surfactant protein (SP)-B are associated with lung
injury and respiratory distress, potential causal relationships between SP-B deficiency and …